N
KIN

Nuveen’s Kindred Biosciences, Inc. KIN Stock Holding History

Nuveen’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-154,713
Closed -$769K – 3628
2021
Q1 		$769K Sell
154,713
-4,021
-3% -$19.4K ﹤0.01% 2980
2020
Q4 		$684K Sell
158,734
-24,718
-13% -$101K ﹤0.01% 2935
2020
Q3 		$787K Buy
183,452
+41,859
+30% +$175K ﹤0.01% 2788
2020
Q2 		$636K Buy
141,593
+15,158
+12% +$67.7K ﹤0.01% 2809
2020
Q1 		$505K Buy
126,435
+8,807
+7% +$74.8K ﹤0.01% 2772
2019
Q4 		$997K Sell
117,628
-1,485
-1% -$11.6K ﹤0.01% 2691
2019
Q3 		$816K Buy
119,113
+4,663
+4% +$34.2K ﹤0.01% 2778
2019
Q2 		$954K Buy
+114,450
New +$988K ﹤0.01% 2763

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Nuveen's KIN Position: Q2 2021 in Review

Nuveen sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 154,713 shares — an estimated $769K sold.

Nuveen first reported a position in KIN in Q2 2019 and held it in 8 quarters. The position peaked at $997K in Q4 2019. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • Nuveen reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 154,713 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $769K.
  • Nuveen first reported a position in Kindred Biosciences, Inc. in Q2 2019 and held it in 8 quarters.
  • Nuveen's Kindred Biosciences, Inc. position peaked at $997K in Q4 2019.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.